Lilly and AstraZeneca gang up on Merck in Alzheimer's
This article was originally published in Scrip
Executive Summary
Eli Lilly is to pay AstraZeneca up to $500m in development and regulatory milestone payments, the first $50m of which could be due in the first half of 2015, under a new deal to jointly develop and commercialize AstraZeneca's AZD3293. The oral beta secretase cleaving enzyme (BACE) inhibitor is currently in early clinical development as a potential treatment for Alzheimer's disease.
You may also be interested in...
Bullish Lilly Adds New Alzheimer's Candidate To Clinical Portfolio
Undaunted by its recent disappointment with solanezumab, Eli Lilly is adding another clinical-stage Alzheimer's disease candidate to its portfolio through an agreement with AstraZeneca.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.